サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1739366

サンガーシーケンスの世界市場

Sanger Sequencing

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.90円
サンガーシーケンスの世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

サンガーシーケンスの世界市場は2030年までに89億米ドルに達する見込み

2024年に34億米ドルと推定されるサンガーシーケンスの世界市場は、2024年から2030年にかけてCAGR 17.5%で成長し、2030年には89億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるショットガンシーケンスは、CAGR 16.3%を記録し、分析期間終了までに54億米ドルに達すると予測されます。ターゲット遺伝子シーケンスセグメントの成長率は、分析期間中CAGR 19.1%と推定されます。

米国市場は8億9,420万米ドルと推定、中国はCAGR16.6％で成長すると予測

米国のサンガーシーケンス市場は、2024年に8億9,420万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.9％と15.3％と予測されています。欧州では、ドイツがCAGR約13.0％で成長すると予測されています。

世界の「サンガーシーケンス」市場- 主要動向と促進要因のまとめ

ゲノミクス主導の世界でサンガーシーケンスが重要であり続ける理由とは？

次世代シーケンス（NGS）プラットフォームの台頭にもかかわらず、サンガーシーケンスはその比類ない精度、シンプルさ、特定のアプリケーションに対する費用対効果により、その関連性を維持しています。配列の検証、単一遺伝子診断、小規模な研究プロジェクトでは、依然としてゴールドスタンダードとなっています。この方法は、臨床ゲノミクスにおいて、ハイスループットメソッドで同定されたバリアントを確認するために高く評価されています。サンガーシーケンスは、しばしば1000塩基対にも及ぶ、長くて忠実度の高いリードを提供できるため、研究者に好まれており、ターゲット領域における挿入、欠失、変異の検出に最適です。診断ラボでは、希少疾患や遺伝性疾患の遺伝子検査に広く使用されています。Sangerの最小限のデータ出力は、特に資源が限られた環境では、保存と解析を簡素化します。また、複雑なNGSワークフローと比較して、ターンアラウンドタイムが速いという利点もあります。ゲノミクス市場が獣医学、農業、微生物学分野へと多様化する中、サンガーシーケンスの堅牢性は、必要不可欠な補完技術となっています。キャピラリー電気泳動システムへの適応性と既存のラボインフラとの統合性は、従来の使用事例と新たな使用事例の両方において、その応用を支え続けています。

テクノロジーはどのようにサンガーシーケンスの精度とアクセシビリティを高めているのか？

最近の進歩は、サンガーシーケンスのワークフローを大幅に改善し、コストを削減し、スループットを向上させています。DNA抽出、PCRクリーンアップ、反応調製の自動化により、手作業によるミスが最小限になり、サンプルハンドリングの効率が向上しました。色素ターミネーター化学とキャピラリー電気泳動システムの改良により、シグナルの明瞭さ、スピード、データ分解能が向上しました。コンパクトなベンチトップシーケンサーにより、小規模ラボやクリニックでの分散型シーケンサーが可能になりました。また、クラウドベースのバイオインフォマティクス・プラットフォームとの統合により、データ解析、解釈、レポート作成が専門家でなくても利用できるようになりました。AIツールは低頻度のバリアントをより高い信頼性で検出するために使用されています。試薬の小型化はサンプルあたりのコスト削減に役立ち、オープンソースの実験器具は教育機関での低コスト導入を促進しています。サンプルのバーコードタグ付けは、より高いレベルの多重化を可能にし、ラボの生産性を高めています。さらに、リアルタイム・モニタリング・ツールは、あらゆる段階での品質管理を確実なものにしています。その結果、サンガーシーケンスは、もはや単なる手作業のラボ手順ではなく、より広範なゲノミクスエコシステムにきちんと適合する、半自動化されたインテリジェントなプラットフォームへと進化しつつあります。

サンガーシーケンスの需要が最も急速に伸びている分野は？

サンガーシーケンスは、正確さと確認が最重要とされる特定の業界において、新たな需要が生じています。臨床診断では、特にがん素因や希少疾患のパネルで、生殖細胞系列変異の確認検査に頻繁に使用されています。薬理ゲノミクスでは、正確なジェノタイピングがオーダーメイド治療に不可欠であり、その役割は拡大しています。農業ゲノミクスもまた成長分野であり、サンガーは作物の遺伝子型判定、形質確認、育種プログラムに利用されています。微生物学では、病原体の同定、抗生物質耐性分析、プラスミドの検証に用いられています。獣医学では、血統書付きの動物の遺伝子スクリーニングや病気の追跡のためにサンガーを採用するケースが増えています。法医学研究所では、その高品質なリード出力により、ミトコンドリアDNA分析にこの方法を使い続けています。教育機関もまた、その信頼性と使いやすさから、シーケンスの基礎を学ぶ学生のトレーニングにサンガーシステムを利用しています。契約研究機関（CRO）へのシーケンスサービスのアウトソーシングの増加は、市場の安定した需要をさらに後押ししています。このような分野特有の要件は、現代のゲノミクスにおける基盤技術としてのサンガー独自の役割を浮き彫りにしています。

サンガーシーケンス市場の成長はいくつかの要因によってもたらされる...

サンガーシーケンス市場の拡大は、永続的な技術的魅力と変化する業界ニーズの融合によって支えられています。臨床診断における高信頼性の確認検査に対する需要は、特に精密医療においてコンパニオン診断が普及するにつれて、その利用を持続させています。学術機関や政府機関における研究イニシアチブの増加も市場拡大に拍車をかけています。費用対効果とセットアップの容易さにより、サンガーは特に発展途上地域の低スループットラボで選択される手法となっています。NGSデータセットの複雑化により、最終的なバリデーションにおけるサンガーシーケンスへの依存度が高まっています。規制機関は、その証明された再現性と正確性により、認可のためにサンガーデータを好みます。ラボの自動化とベンチトップシーケンス装置への継続的な投資により、技術の拡張性が高まっています。さらに、市場は病院、CRO、分子診断企業間の協力関係の拡大からも恩恵を受けています。サンガーシーケンスは、感染症サーベイランスから植物育種まで、幅広いゲノムツールキットの補完的ソリューションとして繁栄しています。

セグメント

タイプ（ショットガンシーケンス、ターゲット遺伝子シーケンス、その他のタイプ）;用途（診断、個別化医療、法医学、その他の用途）;最終用途（政府研究機関、診断ラボ、製薬・バイオテクノロジー企業、その他の最終用途）

調査対象企業の例（全42件）

  • AAT Bioquest
  • Azenta Life Sciences（GENEWIZ）
  • BaseClear
  • BGI Genomics
  • Eurofins Genomics
  • GenScript
  • Illumina
  • LGC Biosearch Technologies
  • Macrogen
  • MCLAB
  • Microsynth AG
  • Nucleics
  • Psomagen
  • QIAGEN
  • Roche Applied Science
  • SeqLab
  • Source BioScience
  • Synlab
  • Thermo Fisher Scientific
  • Zymo Research

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP34316

Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030

The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR

The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.

Global "Sanger Sequencing" Market - Key Trends & Drivers Summarized

Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?

Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.

How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?

Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.

In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?

Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it's frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.

The Growth In The Sanger Sequencing Market Is Driven By Several Factors...

The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.

SCOPE OF STUDY:

The report analyzes the Sanger Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • AAT Bioquest
  • Azenta Life Sciences (GENEWIZ)
  • BaseClear
  • BGI Genomics
  • Eurofins Genomics
  • GenScript
  • Illumina
  • LGC Biosearch Technologies
  • Macrogen
  • MCLAB
  • Microsynth AG
  • Nucleics
  • Psomagen
  • QIAGEN
  • Roche Applied Science
  • SeqLab
  • Source BioScience
  • Synlab
  • Thermo Fisher Scientific
  • Zymo Research

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Sanger Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Continued Use in Targeted DNA Sequencing Applications Sustains Demand for Sanger Sequencing
    • Clinical Diagnostics and Genetic Validation Workflows Strengthen Business Case for Precision Sequencing
    • Pharma and Biotech R&D Activities Throw the Spotlight on Sangers Reliability in Mutation Detection
    • Growing Preference for Low-Throughput, High-Accuracy Techniques in Niche Applications Drives Adoption
    • Cost-Effectiveness in Academic and Clinical Labs Sustains Long-Term Relevance of Sanger Platforms
    • Rising Prevalence of Genetic Disorders Accelerates Use in Confirmatory Testing
    • Expansion of Outsourced Sequencing Services Creates New Demand from Research Institutions
    • Next-Generation Sequencing Limitations in Long Homopolymer Regions Create Opportunities for Sanger
    • Regulatory Compliance in Clinical Genomics Favors Established and Validated Technologies
    • Integration with NGS Workflows for Hybrid Pipelines Expands Market Potential
    • Low Entry Cost and Training Requirements Sustain Adoption in Emerging Markets and Universities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sanger Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Shotgun Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Shotgun Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Targeted Gene Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Targeted Gene Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Forensics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Forensics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • CHINA
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030

IV. COMPETITION